Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence
- 10 May 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Research in Cardiology
- Vol. 103 (11), 855-886
- https://doi.org/10.1007/s00392-014-0720-4
Abstract
Although Helicobacter pylori (Hp) primarily colonizes gastric mucosa, it can occasionally inhabit in atherosclerotic plaques. Both forms of Hp infection may be involved in the pathogenesis of atherosclerosis via activation of a systemic or local inflammatory host reaction and induction of plaque progression and/or instability, possibly leading to coronary syndromes. The association between Hp infection and cardiovascular endpoint prevalence remains uncertain; however, it has been reported in many epidemiological investigations and may be reasonably explained by pathophysiological mechanisms. Besides the inflammatory pathway, Hp infection may trigger acute coronary syndromes by enhanced platelet reactivity and increased risk of gastrointestinal bleeding (type 2 myocardial infarction). The former seems to be predominantly related to the stimulatory effect of Hp infection on von Willebrand factor-binding and P-selectin activation, and the latter results from cytotoxic bacteria properties and aggravation of digestive tract injury related to aspirin or dual antiplatelet therapy. Despite these premises, the role of Hp infection in cardiovascular syndromes should still be recognized as controversial and requiring randomized, controlled trials to evaluate the outcome of Hp eradication in both cardiac and gastroenterological endpoints. Such need is also justified by potential bias of previous studies resulting from (1) using different diagnostic methods for identification of Hp infection, since only a small number of studies required confirmation of active Hp infection; and from (2) common lack of adjustment for important confounders such as socioeconomic status, smoking and effectiveness of eradication therapy, as well as the genetic characteristics of both the host and the bacterium.Keywords
This publication has 131 references indexed in Scilit:
- Comorbidities Affect Risk of Nonvariceal Upper Gastrointestinal BleedingGastroenterology, 2013
- Applications of CYP450 Testing in the Clinical SettingMolecular Diagnosis & Therapy, 2013
- Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trialsClinical Research in Cardiology, 2012
- Value of C-Reactive Protein as a Risk Factor for Acute Coronary Syndrome: A Comparison with Apolipoprotein Concentrations and Lipid ProfileMediators of Inflammation, 2012
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)European Heart Journal, 2011
- Genetic determinants of platelet response to clopidogrelJournal of Thrombosis and Thrombolysis, 2011
- Evaluation of Stress Systems by Applying Noninvasive Methodologies: Measurements of Neuroimmune Biomarkers in the Sweat, Heart Rate Variability and Salivary CortisolNeuroimmunomodulation, 2010
- Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleedingCMAJ : Canadian Medical Association Journal, 2007